Abstract
Many studies have investigated the association between the allergic conditions and the risk of glioma. However, the evidence is inadequate to draw robust conclusions because most studies were generally small and conducted in heterogeneous populations. To shed light on these inconclusive findings, we conducted a meta-analysis of studies relating the allergic conditions to the risk of glioma. We identified the relevant studies by searching ISI Web of Science, PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI) databases, and Wanfang database by October 2013. We included studies that reported odds ratio (OR) or hazard ratio (HR) with its 95 % confidence interval (CI) for the association between the allergic condition and the risk of glioma. Eighteen independent publications, with 9,986 glioma cases and 118,950 controls, were included. Our results showed that allergic condition was reversely associated with the risk of glioma (OR = 0.78, 95 % CI 0.73–0.83, P < 0.001). The results of our meta-analysis indicated that allergic conditions significantly reduce the risk of glioma.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Glioma is the most common type of brain tumor worldwide [1]. The incidence rate of glioma is about six per 100,000 annually [1–3], and the 5-year survival rate is about 20 % [3,4]. However, little is known about the factors that lead to the development of glioma. Exposure to ionizing radiation [5,6], genetic polymorphisms [7–10], and history of a familial cancer such as Li–Fraumeni or Turcot syndrome are well-recognized risk factors, but they explain only a very small proportion of glioma cases. Recently, allergy has been consistently shown to be related to glioma risk [11–28]. Allergy consists of a group of heterogeneous diseases with different underlying mechanisms. However, common allergies including eczema, hay fever, and allergic asthma, characterized by immediate hypersensitivity reactions, are mediated by IgE, which is produced and regulated by the B cells as well as T helper type 2 (Th2) and type 17 (Th17) cells [28–30]. And the level of IgE was also found to be associated with the risk of glioma [31–34]. The glioblastoma patients with elevated IgE had 9 months longer survival than those with normal or borderline IgE levels [31]. In addition, allergy related genetic polymorphisms, such as IL-4R and IL-13 were also reported to be associated with the risk of glioma [35]. These evidences indicated that allergic conditions were associated with glioma. Since the relatively small sample size of a single study may not have enough power to detect slight effects of allergic condition on glioma, meta-analysis may provide more credible evidence by systematically summarizing existed data. Although two meta-analysis [36,37] reports analyzing the relation between allergic conditions and the incidence of glioma had been performed in 2007 and in 2011, respectively, there were several large case-control studies have been published since then [24–28]. In addition, the reported associations have remained inconsistent. Therefore, in this study we have extensively reviewed literature and performed a meta-analysis based on all eligible case-control published data to evaluate the association between allergic conditions and glioma risk.
Materials and methods
Literature search and selection
We carried out a publication search in ISI Web of Science, PubMed, EMBASE, Wanfang database in China, and Chinese National Knowledge Infrastructure (CNKI) databases to identify relevant citations published between January 1979 and October 2013 with the following search terms: "brain tumor", "glioma", "allergy", "atopy", "asthma", "eczema", and "hay fever" by two independent investigators. Publication language was not restricted in our search. Abstract, review or editorials were not included. The references of all identified publications were searched for any additional studies, and the related articles option was used to search for further potentially relevant articles. Studies included in our meta-analysis have to meet the following criteria: (1) case-control or cohort studies investigating the association between allergic conditions and glioma; (2) cases were medically confirmed of glioma; (3) sufficient data for examining an odds ratio (OR) with 95 % confidence interval (CI).
Data extraction
Two investigators independently extracted data and reached a consensus on all of the items. For each study, the following characteristics were collected: the first author's last name, year of publication, country of origin, numbers of cases and controls.
Statistical analysis
Meta-analysis was performed by using RevMan 5.0 software provided by the Cochrane Collaboration (Oxford, UK). We directly used Q-test and I 2 test to examine the heterogeneity between each study. By heterogeneity test, if P > 0.05, we select the Fixed Effect Mode1, and if P < 0.05, we select the Random Effect Mode1 to merge OR. Analysis of sensitivity includes the difference of point estimation and CIs of the combined effects value at a different model, to observe whether it changes the result. To test the publication bias, we used the RevMan 5.0 statistical software to make the funnel plot. The statistical significance of the pooled OR was determined with the Z test, and a P value of <0.05 was considered significant.
Results
Literature search
A flow diagram of the literature search is shown in Fig. 1. Total searches yielded 342 entries. Of these, 301 studies were excluded after reading the title or abstract because of obvious irrelevance to our study aim. Forty-one studies appeared to be potentially relevant for inclusion in our study. Fifteen studies were excluded because of overlapping cases or their data were not extractable. A total of 26 full-text articles were reviewed. Eight studies were further excluded for no control population. Therefore, a total of 18 articles included 17 case-control studies [11–16,18–28] and three cohort studies [17] met the inclusion criteria.
Study characteristics
The characteristics including author information, publication year, number of cases and controls, and OR values and 95 % CIs of included studies were summarized in Table 1. These 18 included studies were published between 1990 and 2013 and comprised a total of 9,986 stroke cases and 118,950 control subjects.
Meta-analysis
An assessment of heterogeneity of 20 studies included for the analysis indicated that the hypothesis of homogeneity could not be accepted (χ 2 = 54.43, I 2 = 65 %, P < 0.001); therefore, the random-effects model was used to calculate the summary OR. As shown in Fig. 2, the ORs ranged from 0.55 to 1.04 amongst these studies. In the pooled analysis, our results showed that allergic condition was inversely associated with the risk of glioma (OR = 0.78, 95 % CI 0.73–0.83, P < 0.001).
Test of sensitivity
For the sensitivity analysis, we deleted one single study from the overall pooled analysis each time to check the influence of the removed data set to the overall ORs. The pooled ORs and 95 % CIs were not significantly altered when any part of the study was omitted, which indicated that any single study had little impact on the overall ORs.
Publication bias
Funnel plot and Egger's test were performed to assess the publication bias of the literature. Egger's test further confirmed the absence of publication bias in this meta-analysis (P > 0.05) (Fig. 3).
Discussion
In this meta-analysis, we found an inverse association of allergic condition with the risk of glioma. The results demonstrated that allergic conditions significantly reduce the risk for developing glioma.
The possible role of allergic conditions in the development of glioma remains poorly understand. Allergy consists of a group of heterogeneous diseases with different underlying mechanisms. However, common allergies including eczema, hay fever, and allergic asthma, characterized by immediate hypersensitivity reactions, are mediated by IgE, which is produced and regulated by the B cells as well as T helper type 2 (Th2) and type 17 (Th17) cells [33,34]. The level of IgE may be a better marker to detect the relation between allergy and glioma because it is not affected by individual recall and reporting. Schwartzbaum et al. [29] reported an inverse association between IgE levels and risk of glioma; the association was present at least 20 years before tumor diagnosis.
The protective role of allergic condition in the development of glioma is also supported by an association between germ line polymorphism and risk of glioma. SNPs and haplotypes in genes encoding IL-4, IL-4R, IL-13 critical for allergy and IgE production are the most intensely studied [35,38,39]. In our meta-analysis, we found the allergic conditions may reduce risk of glioma by 28.0 %. Our result was in line with previous studies. Previously, two meta-analysis [36,37] have reported the relation between allergic conditions and glioma risk. Linos et al. [37] enrolled eight studies with a total of 3,450 patients diagnosed with glioma and 1,070 patients with meningioma. The authors found the pooled relative risks (RRs) of glioma comparing those with a history of an atopic condition with those with no history of that condition were 0.61 (95 % CI, 0.55–0.67) for allergy. In 2011, Chen et al. [36] selected 12 studies to perform a meta-analysis involving 61,090 participants and found that the pooled OR with any allergic conditions for glioma was 0.60 (95 % CI, 0.52–0.69; P < 0.001) which suggesting a significant negative association (protective effect) between allergy and glioma. In the present study, we included 20 studies including 9,986 glioma cases and 118,950 controls and demonstrated this reverse relation between glioma and allergy.
In addition, exploring heterogeneity is one of the important goals of meta-analysis. In this study we found significant heterogeneity among the included studies. Therefore, we utilized the randomly model to merge the OR value. Sensitivity analysis showed that omission of any single study did not have significant impact on the combined ORs. Furthermore, funnel plot did not reflect obvious asymmetry, and Egger's test further indicated no considerable publication bias in this meta-analysis. This made the results of this meta-study more reliable to some extent.
This study has several limitations including the methods of included studies were not the same one. And not all the studies defined the allergy by detecting the IgE level. Moreover, other clinical factors such as age, sex and different chemotherapies in each study might lead to bias. Determining whether or not these factors influence the results of this meta-analysis would need further investigation.
In conclusion, our study suggested that allergic condition was associated with a significantly decreased risk of glioma. Larger well-designed epidemiological studies with ethnically diverse populations and functional evaluations are warranted to confirm our findings.
References
Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg. 1998;88:1–10.
Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. J Neurosurg. 2003;99:458–66.
Fisher PG, Buffler PA. Malignant gliomas in 2005: where to GO from here? JAMA. 2005;293:615–7.
Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.
Fischer U, Rheinheimer S, Krempler A, Löbrich M, Meese E. Glioma-amplified sequence KUB3 influences double-strand break repair after ionizing radiation. Int J Oncol. 2013;43(1):50–6.
Kim RK, Suh Y, Cui YH, Hwang E, Lim EJ, Yoo KC, et al. Fractionated radiation-induced nitric oxide promotes expansion of glioma stem-like cells. Cancer Sci. 2013;104(9):1172–7.
Fan S, Zhao Y, Li X, Du Y, Wang J, Song X, et al. Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population. Exp Biol Med (Maywood). 2013;238(9):1075–81.
Zhao B, Ye J, Li B, Ma Q, Su G, Han R. DNA repair gene XRCC3 Thr241Met polymorphism and glioma risk: a meta-analysis. Int J Clin Exp Med. 2013;6(6):438–43.
Jiang J, Quan XF, Zhang L, Wang YC. The XRCC3 Thr241Met polymorphism influences glioma risk — a meta-analysis. Asian Pac J Cancer Prev. 2013;14(5):3169–73.
Enciso-Mora V, Hosking FJ, Di Stefano AL, et al. Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. Br J Cancer. 2013;108(10):2178–85.
Hochberg F, Toniolo P, Cole P, Salcman M. Nonoccupational risk indicators of glioblastoma in adults. J Neurooncol. 1990;8:55–60.
Ryan P, Lee MW, North B, McMichael AJ. Risk factors for tumors of the brain and meninges: results from the Adelaide Adult Brain Tumor Study. Int J Cancer. 1992;51:20–7.
Schlehofer B, Blettner M, Becker N, Martinsohn C, Wahrendorf J. Medical risk factors and the development of brain tumors. Cancer. 1992;69:2541–7.
Cicuttini FM, Hurley SF, Forbes A, et al. Association of adult glioma with medical conditions, family and reproductive history. Int J Cancer. 1997;71:203–7.
Schlehofer B, Blettner M, Preston-Martin S, et al. Role of medical history in brain tumour development. Results from the international adult brain tumor study. Int J Cancer. 1999;82:155–60.
Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M. History of allergies among adults with glioma and controls. Int J Cancer. 2002;98:609–15.
Schwartzbaum J, Jonsson F, Ahlbom A, et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer. 2003;106:423–8.
Schoemaker MJ, Swerdlow AJ, Hepworth SJ, McKinney PA, van Tongeren M, Muir KR. History of allergies and risk of glioma in adults. Int J Cancer. 2006;119:2165–72.
Schwartzbaum JA, Ahlbom A, Lonn S, et al. An international case–control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2448–54.
Wigertz A, Lonn S, Schwartzbaum J, et al. Allergic conditions and brain tumor risk. Am J Epidemiol. 2007;166:941–50.
Scheurer ME, El-Zein R, Thompson PA, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1277–81.
Berg-Beckhoff G, Schuz J, Blettner M, et al. History of allergic disease and epilepsy and risk of glioma and meningioma (INTERPHONE study group, Germany). Eur J Epidemiol. 2009;24:433–40.
Wiemels JL, Wilson D, Patil C, et al. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009;125:680–7.
Lachance DH, Yang P, Johnson DR, et al. Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. Am J Epidemiol. 2011;174(5):574–81.
McCarthy BJ, Rankin K, Il'yasova D, Erdal S, Vick N, Ali-Osman F, et al. Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol Biomarkers Prev. 2011;20(2):370–8.
Lee ST, Bracci P, Zhou M, Rice T, Wiencke J, Wrensch M, et al. Interaction of allergy history and antibodies to specific varicella–zoster virus proteins on glioma risk. Int J Cancer. 2013. doi:10.1002/ijc.28535.
Safaeian M, Rajaraman P, Hartge P, Yeager M, Linet M, Butler MA, et al. Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma risk. Cancer Causes Control. 2013;24(10):1885–91.
Turner MC, Krewski D, Armstrong BK, Chetrit A, Giles GG, Hours M, et al. Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand. Cancer Causes Control. 2013;24(5):949–60.
Schwartzbaum J, Ding B, Johannesen TB, Osnes LT, Karavodin L, Ahlbom A, et al. Association between prediagnostic IgE levels and risk of glioma. J Natl Cancer Inst. 2012;104(16):1251–9.
Turner MC. Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother. 2012;61(9):1493–510.
Lin Y, Jin Q, Zhang GZ, Wang YJ, Jiang T, Wu AH, et al. Increase of plasma IgE during treatment correlates with better outcome of patients with glioblastoma. Chin Med J (Engl). 2011;124(19):3042–8.
Calboli FC, Cox DG, Buring JE, Gaziano JM, Ma J, Stampfer M, et al. Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies. J Natl Cancer Inst. 2011;103(21):1588–95.
Schlehofer B, Siegmund B, Linseisen J, et al. Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. Allergy. 2011;66(11):1434–41.
Wiemels JL, Wrensch M, Sison JD, Zhou M, Bondy M, Calvocoressi L, et al. Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls. Int J Cancer. 2011;129(8):1932–9.
Scheurer ME, Amirian E, Cao Y, et al. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res. 2008;14:6640–6.
Chen C, Xu T, Chen J, Zhou J, Yan Y, Lu Y, et al. Allergy and risk of glioma: a meta-analysis. Eur J Neurol. 2011;18(3):387–95.
Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99(20):1544–50.
Ruan Z, Zhao Y, Yan L, Chen H, Fan W, Chen J, et al. Single nucleotide polymorphisms in IL-4Ra, IL-13 and STAT6 genes occurs in brain glioma. Front Biosci (Elite Ed). 2011;3:33–45.
Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, et al. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res. 2005;65(14):6459–65.
Acknowledgments
This work was supported by National Natural Science Foundation grant from China National Science Foundation Committee (No: 81172410).
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhao, H., Cai, W., Su, S. et al. Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects. Tumor Biol. 35, 3875–3880 (2014). https://doi.org/10.1007/s13277-013-1514-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-1514-4